Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on OncoMed Pharmaceuticals, Inc.

by

Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

OncoMed Pharmaceuticals is a U.S. public bio/pharmaceutical company that discovers and develops mAbs and small molecules for the treatment of cancer. It has raised $59.2 million in a secondary public offering, as reported in the PharmSource Lead Sheet on August 25, 2016.

Corporate Highlights

  • OncoMed Pharmaceuticals was incorporated in Delaware in 2004
  • Corporate Headquarters: Redwood City, CA – approximately 45,690 square feet of office and laboratory space
  • As of March 10, 2016, they had 122 employees.
  • Stock Exchange: NASDAQ
  • Stock Symbol: OMED

Sourcing Opportunities

  • OncoMed Pharmaceuticals plans to use the proceeds to support R&D efforts of its pipeline, possibly including:
    • OMP-21M18 (Demcizumab) – To complete a Phase IIa study:
      • For treatment of metastatic pancreatic cancer
      • Dosage Form: Parenteral
      • Nature of API: Biologic – Monoclonal antibody
      • Therapeutic Area: Oncology – Immunotherapy; Oncology – Chemotherapy
    • OMP-305B83 – To complete Phase Ia study:
      • For treatment of cancer
      • Dosage Form: Parenteral
      • Nature of API: Biologic – Antibody
      • Therapeutic Area: Oncology – Immunotherapy
  • The company contracts with contract research organizations (CROs) to conduct clinical trials.
  • OncoMed Pharmaceuticals does not own or operate manufacturing facilities and relies on third party contract manufacturers for all required raw materials, API and finished product for preclinical studies and clinical trials.
  • OncoMed Pharmaceuticals has no sales, marketing or distribution capabilities or experience.

Business Relationships

  • In December 2013, OncoMed Pharmaceuticals and Celgene entered into a collaboration agreement to jointly develop and commercialize up to six anticancer stem cell product candidates from OncoMed’s biologics pipeline, including demcizumab. OncoMed received an upfront payment of $177.2 million and could receive up to $3.3 billion in option exercise payments and milestones.
  • In June 2010, OncoMed Pharmaceuticals and Bayer Schering Pharma entered into a global alliance to discover, develop and commercialize anticancer stem cell therapeutics, antibodies, protein therapeutics and small molecules that target the Wnt signaling pathway. OncoMed received an upfront cash payment of $40 million and $50 million in milestone payments to date specific to vantictumab and ipafricept.
  • In December 2007, OncoMed Pharmaceuticals and GlaxoSmithKline entered into an alliance to develop antibody therapeutics to treat cancer. OncoMed received a total of $35 million, including an upfront payment of $17.5 million and $17.5 million in an equity investment. OncoMed was also eligible to earn milestone payments up to $1.4 billion from GSK based on the achievement of specified discovery, development, regulatory and commercial milestones.1

Drug Product Pipeline

Product Candidate Indication Dosage Form Status Next Anticipated Step
WNT inhibitors Cancer Unknown Preclinical TBA
GITRL-Fc
(IO#3)
Immuno-oncology
Therapy
Unknown Preclinical TBA
GITRL-Fc
(IO#2)
Immuno-oncology
Therapy
Unknown Preclinical IND application in 2016/2017
GITRL-Fc Immuno-oncology
Therapy
Parenteral Preclinical IND application in 2016/2017
OMP-305B83 Cancer Parenteral Phase Ia TBA
OMP-52M51
(Brontictuzumab)
BSolid Tumors Parenteral Phase Ia TBA
OMP-131R10 Advanced Refractory
Solid Tumors
Parenteral Phase Ia/Ib TBA
OMP-54F28
(Ipafricept)
Ovarian/Hepatocellular/Pancreatic Cancer Parenteral Phase Ib TBA
OMP-18R5
(Vantictumab)
Pancreatic/Breast/NSCL
Cancer
Parenteral Phase Ib TBA
OMP-59R5
(Tarextumab)
Pancreatic/NSCL
Cancer
Parenteral Phase II TBA
OMP-21M18
(Demcizumab)
Pancreatic/NSCL/Ovarian
Cancer
Parenteral Phase II TBA

Finances

(In $ thousands) 2015 2014
Revenues
25,216
39,559
R&D Expenditures
92,873
76,430
General & Administrative Expenditures
18,583
13,753
Total Operating Expenses
111,456
90,183

1OncoMed Pharmaceuticals, Inc. 3/10/16 10-K, SEC.gov

Contact Information

OncoMed Pharmaceuticals, Inc. Key Officers
800 Chesapeake Drive Paul J. Hastings, President & CEO
Redwood City, CA, 94063 USA Sylvia Wu, Manager, QC
Phone: +1-650-995-8200 John Lewicki, PhD, EVP & CSO
Fax: +1-650-995-8600 Jakob Dupont, MD, CMO & SVP
Web: www.oncomed.com Jill Henrich, VP, Regulatory Affairs

Related posts:
Follow the Money to Pharmaceutical Opportunities – Spotlight on Galena Biopharma, Inc.
Follow the Money to Pharmaceutical Opportunities – Spotlight on Medgenics, Inc.
Follow the Money to Pharmaceutical Opportunities – Spotlight on Ignyta, Inc.

Scotty is a Research Analyst at PharmSource. He holds a BS degree in Biology from George Mason University and an MPH degree from Eastern Virginia Medical School. He’s experienced in data collection, analysis and management, and has done laboratory analysis and safety program development.

More posts by Scotty Chung-Siu